Innate Pharma (IPHA) Revenue (2019 - 2024)
Historic Revenue for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to $8.9 million.
- Innate Pharma's Revenue fell 8413.06% to $8.9 million in Q4 2024 from the same period last year, while for Jun 2025 it was $78.8 million, marking a year-over-year decrease of 5141.44%. This contributed to the annual value of $21.8 million for FY2024, which is 6733.9% down from last year.
- Latest data reveals that Innate Pharma reported Revenue of $8.9 million as of Q4 2024, which was down 8413.06% from $14.1 million recorded in Q2 2024.
- Innate Pharma's 5-year Revenue high stood at $67.0 million for Q4 2020, and its period low was $8.9 million during Q4 2024.
- Over the past 5 years, Innate Pharma's median Revenue value was $30.1 million (recorded in 2022), while the average stood at $33.8 million.
- As far as peak fluctuations go, Innate Pharma's Revenue skyrocketed by 26507.41% in 2022, and later crashed by 8413.06% in 2024.
- Innate Pharma's Revenue (Quarter) stood at $67.0 million in 2020, then plummeted by 79.31% to $13.9 million in 2021, then skyrocketed by 265.07% to $50.6 million in 2022, then rose by 10.4% to $55.8 million in 2023, then plummeted by 84.13% to $8.9 million in 2024.
- Its Revenue was $8.9 million in Q4 2024, compared to $14.1 million in Q2 2024 and $55.8 million in Q4 2023.